Please use this identifier to cite or link to this item:
Title: Expression of oral secretory leukocyte protease inhibitor in HIV-infected subjects with long-term use of antiretroviral therapy
Authors: Nittayananta W.
Kemapunmanus M.
Yangngam S.
Talungchit S.
Sriplung H.
Keywords: antiretrovirus agent
messenger RNA
nonnucleoside reverse transcriptase inhibitor
proteinase inhibitor
RNA directed DNA polymerase inhibitor
secretory leukocyte proteinase inhibitor
CD4 lymphocyte count
controlled study
enzyme linked immunosorbent assay
Human immunodeficiency virus
Human immunodeficiency virus infection
innate immunity
major clinical study
priority journal
protein expression
real time polymerase chain reaction
virus load
Alcohol Drinking
Anti-HIV Agents
Anti-Retroviral Agents
Biological Markers
CD4 Lymphocyte Count
Cross-Sectional Studies
Gingival Hemorrhage
HIV Infections
Middle Aged
Mouth Mucosa
Oral Health
Periodontal Pocket
Salivary Proteins and Peptides
Secretory Leukocyte Peptidase Inhibitor
Secretory Rate
Serine Proteinase Inhibitors
Time Factors
Viral Load
Young Adult
Issue Date: 2013
Abstract: Background: The objectives of this study were to determine (i) the expression of oral secretory leukocyte protease inhibitor (SLPI) in HIV-infected subjects compared with non-HIV controls, (ii) the oral SLPI expression in HIV-infected subjects with antiretroviral therapy (ART) compared with those without ART, and (iii) factors associated with the expression of oral SLPI. Methods: Oral tissues and samples of both un-stimulated and stimulated saliva were collected from HIV-infected subjects with and without ART, and non-HIV individuals. The expression of SLPI mRNA in the tissue was determined by quantitative real-time PCR. Salivary SLPI protein was detected using ELISA. Chi-square test and logistic regression analysis were performed to determine the association between HIV/ART status and the expression of oral SLPI. Results: One hundred and fifty-seven HIV-infected subjects were enrolled: 99 on ART (age range, 23-57 years; mean, 39 years), 58 not on ART (age range, 20-59 years; mean, 34 years), and 50 non-HIV controls (age range, 19-59 years; mean, 36 years). The most common ART regimen was 2NRTIs + 1NNRTI. The expression of oral SLPI in stimulated saliva was significantly decreased with HIV infection (P < 0.001). The expression was also significantly different with respect to ART use (P = 0.007). Smoking, CD4+ cell count, and HIV viral load were the factors associated with the oral SLPI expression. Conclusion: The expression of oral SLPI is altered by HIV infection and use of ART. Thus, oral SLPI may be the useful biomarker to identify subjects at risk of infections and malignant transformation due to HIV infection and long-term ART.© 2012 John Wiley & Sons A/S. Published by Blackwell Publishing Ltd.
ISSN: 9042512
Appears in Collections:Scopus 1983-2021

Files in This Item:
There are no files associated with this item.

Items in SWU repository are protected by copyright, with all rights reserved, unless otherwise indicated.